HV 1058-1

HV 1058-1 is an enteral nutrition formulation developed by Fresenius Kabi Deutschland GmbH. It is designed for nutritional support, typically administered via the oral or enteral route (tube feeding) for patients with specific metabolic or clinical requirements. The formulation has been evaluated in clinical research, specifically in a completed study (NCT02441205) involving healthy volunteers to measure its glycaemic index (GI) compared to oral glucose. This characterization helps determine the postprandial glucose response and metabolic impact of the formulation, which is critical for managing patients with impaired glucose tolerance or those requiring specialized medical foods.